Republica Moldova -
română -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
rotarix™ suspensie orala
glaxosmithkline biologicals s.a. - vaccin rotavirus - suspensie orala
Uniunea Europeană -
română -
EMA (European Medicines Agency)
vidaza
bristol-myers squibb pharma eeig - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
Uniunea Europeană -
română -
EMA (European Medicines Agency)
azacitidine celgene
celgene europe bv - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
Uniunea Europeană -
română -
EMA (European Medicines Agency)
azacitidine mylan
mylan ireland limited - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
Uniunea Europeană -
română -
EMA (European Medicines Agency)
arsenic trioxide accord
accord healthcare s.l.u. - trioxid de arsen - leucemie, promielocitară, acută - agenți antineoplazici - trioxidul de arsen este indicat pentru inducerea remisiunii și consolidare la pacienții adulți cu:nou diagnosticate low-la-risc intermediar leucemie acută promielocitară (lap) (celule albe din sânge, ≤ 10 x 103/µl) în combinație cu all-trans acid retinoic (atra)a recidivat/refractar leucemie acută promielocitară (lap)(tratamentul anterior trebuie să fi inclus un retinoid și chimioterapie), caracterizată prin prezența t(15;17) translocație și/sau prezența de leucemie promielocitară/retinoic acid-receptor-alfa (pml/rar-alfa) gene. rata de răspuns de alte leucemie mieloidă acută subtipuri de trioxid de arsen nu a fost examinată.
Republica Moldova -
română -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
cervarix™ suspensie injectabila 1 doza
glaxosmithkline biologicals s.a. - vaccin papilomavirus uman (tipurile 16 dacă 18) - suspensie injectabila - 1 doza
